Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pending Biosimilars

Executive Summary

Biosimilar applications using the 351(k) pathway under review at FDA. Updated upon new submissions.

Advertisement

Related Content

US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis

Topics

Advertisement
UsernamePublicRestriction

Register

PS057500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel